Protagonist Therapeutics stock
PTGXNASDAQProtagonist Therapeutics, Inc., HealthcareISIN US74366E1029
68Score 68 out of 100, Neutral
Price and trend
65 / 100
Price history
+58% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since March 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 15% below its 52-week high. Largest decline in 10 years: 86% (September 2021 to June 2022).
Chart figures for advanced users
- SMA 50$140.66
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$119.03
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$79.73
- The lowest closing price of the last twelve months.
- Resistance$158.62
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Protagonist Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $8.77B, is number 44 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $46.02M (down 89.4% year on year) and a loss of $130.15M.
- For fiscal 2026, analysts expect on average revenue of $565.46M (up 1,128.8%) and adjusted earnings per share of $5.18.
Show more
- MEQIRI Score 68 out of 100 (Neutral): rank 168 of 702 in Healthcare, median 53.
- The P/E is 28.2 (Biotechnology median 21.7, own median of recent years 8.6).
- Our model puts fair value at $114.81, with the price 17% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 62% over the last 12 months, Biotechnology median −103.7%.Profitability 98
- More cash than debtCash $800.06M, financial debt $8.63M.Stability 78
Weaknesses
- DilutionShare count up 85% since 2020.Capital allocation 54
- Analysts expect falling earningsDown 40.7% a year through 2028 (estimates from 8 analysts).
Its standout strengths are profitability and momentum, while valuation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $88.32 and expensive above $164.02 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $125.99 (cash-flow model) and $103.64 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $105.02, at 8.2% it would be $129.05.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 89.4% on the prior year. Revenue turned from negative at the start of the period to positive ($46.02M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 97%, operating −344%, net −283%. Last 12 months: net 62%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 24 Feb 2027in 103 days
- Last reported
- 5 Nov 2026EPS reported $3.07 (expected $3.06)in line with expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 93.9% since 15 Oct 2026.
- Earnings per share
- $5.18+12.8%
- Revenue
- $565.46M+4.2%
- Earnings per share
- −$0.03+93.9%
- Revenue
- $227.49M+13.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $44.37M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Ali AsifSale
30 Sept 2026, Chief Financial Officer
- Shares
- 58,629
- Price
- $141.78
- Value
- $8.31M
- Patel Dinesh V Ph DSale
10 Sept 2026, President and CEO
- Shares
- 7,278
- Price
- $144.10
- Value
- $1.05M
- Patel Dinesh V Ph DSale
9 Sept 2026, President and CEO
- Shares
- 63,548
- Price
- $146.18
- Value
- $9.29M
Show 6 more
- Patel Dinesh V Ph DSale
8 Sept 2026, President and CEO
- Shares
- 54,174
- Price
- $145.87
- Value
- $7.9M
- Patel Dinesh V Ph DSale
11 Aug 2026, President and CEO
- Shares
- 34,239
- Price
- $148.52
- Value
- $5.09M
- Patel Dinesh V Ph DSale
10 Aug 2026, President and CEO
- Shares
- 65,761
- Price
- $149.11
- Value
- $9.81M
- Waddill William D.Sale
23 Jun 2026, Board
- Shares
- 9,000
- Price
- $117.94
- Value
- $1.06M
- Waddill William D.Sale
10 Jun 2026, Board
- Shares
- 9,000
- Price
- $107.68
- Value
- $969,120
- Waddill William D.Sale
29 May 2026, Board
- Shares
- 9,000
- Price
- $99.64
- Value
- $896,760
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Protagonist Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 68
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Alteogen196170.KQ $9.26B57
- Genscript Biotech1548.HK $9.09B48
- Praxis Precision MedicinesPRAX $9.08B42
- Krystal BiotechKRYS $9.06B66
- Asymchem Laboratories (Tianjin)002821.SZ $8.29B64
- RemeGen688331.SS $8.26B44
- ALK-AbellóALK-B.CO $8.18B74
- AbivaxABVX.PA $8B35
ETFs that hold Protagonist Therapeutics
Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.61% | 0.40% | €813.42M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.58% | 0.35% | €1.25B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.49% | 0.30% | €2.31B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.28% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.28% | 0.30% | €4.28B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.18% | 0.30% | €185.82M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.14% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.12% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026, previously Weak
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.